Revisiting coexisting chromosomal abnormalities in NPM1-mutated
AML in light of the revised ELN 2022 classification

J 2023

Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification

ANGENENDT, Linus; Christoph ROELLIG; Pau MONTESINOS; Farhad RAVANDI; Gunnar JULIUSSON et al.

Základní údaje

Originální název

Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification

Autoři

ANGENENDT, Linus; Christoph ROELLIG; Pau MONTESINOS; Farhad RAVANDI; Gunnar JULIUSSON; Christian RECHER; Raphael ITZYKSON; Zdeněk RÁČIL; Andrew H WEI a Christoph SCHLIEMANN

Vydání

Blood, Washington DC, USA, American Society of Hematology, 2023, 0006-4971

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 21.100

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/23:00133730

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

NPM1-mutated AML

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 3. 2024 10:03, Mgr. Tereza Miškechová

Anotace

V originále

Mutations in the nucleophosmin 1 (NPM1) gene are among the most frequent genetic alterations in patients with acute myeloid leukemia (AML) and have been associated with a favorable prognosis.1,2 In 2019, in a large international collaborative study, we have reported that cytogenetic abnormalities are important determinants of outcome in NPM1-mutated (NPM1mut) AML.3 We showed that intensively treated patients with NPM1mut AML and coexisting adverse-risk cytogenetics shared the same unfavorable prognosis as their NPM1 wild-type (NPM1WT) counterparts. This was a new finding, because the European LeukemiaNet (ELN) 2017 classification considered the NPM1mut status (in the absence of an FLT3-ITD mutation with a high allelic ratio) favorable regardless of accompanying chromosomal abnormalities, in full analogy to core-binding factor AML.4 As a consequence, in the recently published ELN 2022 genetic risk classification of AML, the presence of adverse-risk cytogenetics now defines adverse-risk in NPM1mut AML.5 Other key changes made to the previous ELN classification included the addition of further disease-defining recurrent cytogenetic abnormalities to the adverse-risk group [ie, t(3q26.2;v) and t(8;16)(p11;p13)]. In turn, hyperdiploid karyotypes with multiple (≥3) trisomies or polysomies in the absence of structural abnormalities are no longer considered as complex karyotypes.5,6 Even though the combination of an NPM1 mutation with adverse chromosomal aberrations is a rare event (∼3%), the impact of cytogenetics in NPM1mut AML has important implications for postremission treatment decisions.

Citovat

ANGENENDT, Linus; Christoph ROELLIG; Pau MONTESINOS; Farhad RAVANDI; Gunnar JULIUSSON; Christian RECHER; Raphael ITZYKSON; Zdeněk RÁČIL; Andrew H WEI a Christoph SCHLIEMANN. Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification. Blood. Washington DC, USA: American Society of Hematology, 2023, roč. 141, č. 4, s. 433-435. ISSN 0006-4971. Dostupné z: https://doi.org/10.1182/blood.2022018582.

@article{2381697,
   author = {Angenendt, Linus and Roellig, Christoph and Montesinos, Pau and Ravandi, Farhad and Juliusson, Gunnar and Recher, Christian and Itzykson, Raphael and Ráčil, Zdeněk and Wei, Andrew H and Schliemann, Christoph},
   article_location = {Washington DC, USA},
   article_number = {4},
   doi = {https://doi.org/10.1182/blood.2022018582},
   keywords = {NPM1-mutated AML},
   language = {eng},
   issn = {0006-4971},
   journal = {Blood},
   title = {Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification},
   url = {https://ashpublications.org/blood/article/141/4/433/486979/Revisiting-coexisting-chromosomal-abnormalities-in},
   volume = {141},
   year = {2023}
}

TY  - JOUR
ID  - 2381697
AU  - Angenendt, Linus - Roellig, Christoph - Montesinos, Pau - Ravandi, Farhad - Juliusson, Gunnar - Recher, Christian - Itzykson, Raphael - Ráčil, Zdeněk - Wei, Andrew H - Schliemann, Christoph
PY  - 2023
TI  - Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification
JF  - Blood
VL  - 141
IS  - 4
SP  - 433-435
EP  - 433-435
PB  - American Society of Hematology
SN  - 00064971
KW  - NPM1-mutated AML
UR  - https://ashpublications.org/blood/article/141/4/433/486979/Revisiting-coexisting-chromosomal-abnormalities-in
N2  - Mutations in the nucleophosmin 1 (NPM1) gene are among the most frequent genetic alterations in patients with acute myeloid leukemia (AML) and have been associated with a favorable prognosis.1,2 In 2019, in a large international collaborative study, we have reported that cytogenetic abnormalities are important determinants of outcome in NPM1-mutated (NPM1mut) AML.3 We showed that intensively treated patients with NPM1mut AML and coexisting adverse-risk cytogenetics shared the same unfavorable prognosis as their NPM1 wild-type (NPM1WT) counterparts. This was a new finding, because the European LeukemiaNet (ELN) 2017 classification considered the NPM1mut status (in the absence of an FLT3-ITD mutation with a high allelic ratio) favorable regardless of accompanying chromosomal abnormalities, in full analogy to core-binding factor AML.4 As a consequence, in the recently published ELN 2022 genetic risk classification of AML, the presence of adverse-risk cytogenetics now defines adverse-risk in NPM1mut AML.5 Other key changes made to the previous ELN classification included the addition of further disease-defining recurrent cytogenetic abnormalities to the adverse-risk group [ie, t(3q26.2;v) and t(8;16)(p11;p13)]. In turn, hyperdiploid karyotypes with multiple (≥3) trisomies or polysomies in the absence of structural abnormalities are no longer considered as complex karyotypes.5,6 Even though the combination of an NPM1 mutation with adverse chromosomal aberrations is a rare event (∼3%), the impact of cytogenetics in NPM1mut AML has important implications for postremission treatment decisions.
ER  -

ANGENENDT, Linus; Christoph ROELLIG; Pau MONTESINOS; Farhad RAVANDI; Gunnar JULIUSSON; Christian RECHER; Raphael ITZYKSON; Zdeněk RÁČIL; Andrew H WEI a Christoph SCHLIEMANN. Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification. \textit{Blood}. Washington DC, USA: American Society of Hematology, 2023, roč.~141, č.~4, s.~433-435. ISSN~0006-4971. Dostupné z: https://doi.org/10.1182/blood.2022018582.

Přehled o publikaci